PLAU and neoplasm: Recently we showed that primary breast cancer patients with high tumour levels of uPA and its inhibitor PAI-1, being classified as high risk for recurrence, experienced an enhanced benefit from adjuvant chemotherapy (Harbeck et al, 2002a, 2002b).